Prostate-specific membrane antigen (PSMA) is a type II integral membrane protein that is expressed on the surface of prostate epithelial cells.1 PSMA is upregulated in most prostate tumors,2-4 and its expression levels increase with disease progression and in the transition to metastatic castration-resistant prostate cancer (mCRPC).1,3 PSMA is also expressed on the vasculature of non-prostate tumors, including lung cancer.3,4 Therefore, PSMA is an attractive target for the treatment of prostate cancer and potentially other solid tumors.2-4

Learn more about modalities targeting PSMA:
BiTE® technology.


MCL video

Watch this video to learn more about the role of PSMA in metastatic castration-resistant prostate cancer and the mechanism of action of PSMA-targeted BiTE® molecules

Search our clinical trials.

Visit our resources section for additional information on potential oncogenic targets.


1. Caromile LA, Dortche K, Rahman MM, et al. Sci Signal. 2017;10(470):eaag3326. 2. Wright GL Jr, Grob BM, Haley C, et al. Urology. 1996;48(2):326-334. 3. Ross JS, Sheehan CE, Fisher HAG, et al. Clin Cancer Res. 2003;9(17):6357-6362. 4. Van de Wiele C, Sathekge M, de Spiegeleer B, et al. Histol Histopathol. 2020;35(9):919-927.